Geneva, Switzerland & Barcelona, Spain – January 22, 2026 - ABCDx, a diagnostics company developing blood-based solutions for brain injury and acute neurological conditions, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a new patent covering prospective blood biomarkers for outcome prediction and post-concussion syndrome in adults with traumatic brain injury (TBI).
This newly granted U.S. patent expands ABCDx’s intellectual property portfolio in TBI beyond diagnosis into prognosis and outcome assessment, reinforcing the company’s long-term platform strategy in brain injury biomarkers.
Building a coherent TBI biomarker platform
The newly granted patent complements:
-A previously granted U.S. patent covering adult TBI diagnostics, and
-A peer-reviewed scientific publication in the Journal of Neurotrauma demonstrating biomarker performance in pediatric TBI.
Together, these assets position ABCDx as a company developing a continuum of blood-based tools addressing diagnosis, risk stratification, and outcome prediction in TBI.
Alignment with regulatory strategy
While ABCDx’s current regulatory interactions focus on clearly defined intended uses and analytical performance-driven submissions, this patent provides important future optionality without adding complexity or risk to ongoing FDA programs.
The granted claims support the company’s long-term vision of developing objective, blood-based measurements to complement clinical assessment in brain injury, in line with evolving regulatory expectations for robust, quantitative diagnostic tools.
Strengthening U.S. IP protection
The patent was granted based on an application filed by the Université de Genève and licensed to ABCDx. The company is currently evaluating the filing of divisional applications to further protect commercially relevant claim scope in the United States.
“This patent further strengthens the foundation of our TBI program in the U.S. and reinforces the coherence of our biomarker platform strategy,” said Jean-Charles Sanchez, CEO and Co-founder of ABCDx. “While our near-term regulatory focus remains disciplined and targeted, this milestone secures important long-term value for future clinical and regulatory expansions.”
About ABCDx
ABCDx is a Swiss-Spanish diagnostics company developing blood-based tests for brain injury and acute neurological conditions. Its portfolio spans stroke, traumatic brain injury, and related indications, with a focus on rapid, objective, and clinically action able biomarkers.
Media Contact
Tamara Sefcovicova
PR, Marketing and Office Operations Specialist
